Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,095 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
Dong X, Zhou ZM, Bi N, Wang JB, Ran JT, Hui ZG, Liang J, Feng QF, Chen DF, Xiao ZF, Lyu JM, Wang XZ, Wang X, Zhang T, Deng L, Wang WQ, Wang LH. Dong X, et al. Among authors: wang x, wang lh, wang xz, wang jb, wang wq. Zhonghua Zhong Liu Za Zhi. 2018 Jun 23;40(6):446-451. doi: 10.3760/cma.j.issn.0253-3766.2018.06.009. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29936771 Chinese.
[Technical advancement improves survival in patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving definitive radiotherapy].
Wang JB, Jiang W, Ji Z, Cao JZ, Liu LP, Men Y, Xu C, Wang XZ, Hui ZG, Liang J, Lyu JM, Zhou ZM, Xiao ZF, Feng QF, Chen DF, Zhang HX, Yin WB, Wang LH. Wang JB, et al. Among authors: wang lh, wang xz. Zhonghua Zhong Liu Za Zhi. 2016 Aug;38(8):607-14. doi: 10.3760/cma.j.issn.0253-3766.2016.08.008. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 27531481 Chinese.
[Study on safety of adjuvant radiotherapy concurrent with weekly chemotherapy for stage ⅡB-ⅣA esophageal carcinoma after radical resection].
Ni WJ, Yu SF, Yang JS, Zhang WC, Zhou ZM, Zhang HX, Chen DF, Feng QF, Lyu JM, Liang J, Wang XZ, Wang X, Deng L, Wang WQ, Zhang T, Bi N, Xiao ZF. Ni WJ, et al. Among authors: wang x, wang xz, wang wq. Zhonghua Zhong Liu Za Zhi. 2019 Jun 23;41(6):415-420. doi: 10.3760/cma.j.issn.0253-3766.2019.06.004. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31216826 Chinese.
[Establishment of the method for measuring upper airway critical closing pressure].
Sun T, Diao HL, Sun YL, Wang JY, Wang XZ, Liu JH, Zhang K, Yang JB, Dong XS, Lyu CJ, Han F. Sun T, et al. Among authors: wang jy, wang xz. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Nov 12;43(11):953-957. doi: 10.3760/cma.j.cn112147-20191217-00836. Zhonghua Jie He He Hu Xi Za Zhi. 2020. PMID: 33137862 Chinese.
Eye-Preserving Therapies for Advanced Retinoblastoma: A Multicenter Cohort of 1678 Patients in China.
Zhou C, Wen X, Ding Y, Ding J, Jin M, Liu Z, Wang S, Han M, Yuan H, Xiao Y, Wu L, Wang J, Li Y, Yu J, Wen Y, Ye J, Liu R, Chen Z, Xue S, Lu W, Liao H, Cui J, Zhu D, Lu F, Tang S, Wu Y, Yangkyi T, Zhang G, Wubuli M, Guo H, Wang X, He Y, Sheng X, Wang Q, Luo Y, Fan J, Qi J, Yu Z, Tan J, Liang J, Sun X, Jin L, Yang X, Zhang J, Ji X, Zhao J, Jia R, Fan X. Zhou C, et al. Ophthalmology. 2022 Feb;129(2):209-219. doi: 10.1016/j.ophtha.2021.09.002. Epub 2021 Sep 15. Ophthalmology. 2022. PMID: 34536465
Contemporary Update of Retinoblastoma in China: Three-Decade Changes in Epidemiology, Clinical Features, Treatments, and Outcomes.
Luo Y, Zhou C, He F, Fan J, Wen X, Ding Y, Han Y, Ding J, Jin M, Liu Z, Wang S, Han M, Yuan H, Sun H, Xiao Y, Wu L, Wang J, Li Y, Yang H, Yu J, Gong J, Xu Y, Wen Y, Gao Z, Mei L, Ye J, Liu H, Chen Z, Xue S, Liu R, Chen H, Lu W, Liao H, Guo Q, Cui J, Zhu D, Lu F, Tang S, Wu Y, Yangkyi T, Guanghong Z, Wubuli M, Huiyu G, Wang X, He Y, Sheng X, Wang Q, Tan J, Liang J, Sun X, Zhang J, Ji X, Jin L, Zhao J, Yang X, Jia R, Fan X. Luo Y, et al. Am J Ophthalmol. 2022 Apr;236:193-203. doi: 10.1016/j.ajo.2021.09.026. Epub 2021 Oct 6. Am J Ophthalmol. 2022. PMID: 34626572
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.
Xu B, Zhang Q, Hu X, Li Q, Sun T, Li W, Ouyang Q, Wang J, Tong Z, Yan M, Li H, Zeng X, Shan C, Wang X, Yan X, Zhang J, Zhang Y, Wang J, Zhang L, Lin Y, Feng J, Chen Q, Huang J, Zhang L, Yang L, Tian Y, Shang H. Xu B, et al. Acta Pharm Sin B. 2023 May;13(5):2250-2258. doi: 10.1016/j.apsb.2023.02.001. Epub 2023 Feb 9. Acta Pharm Sin B. 2023. PMID: 37250148 Free PMC article. Clinical Trial.
1,095 results